stockrowUnited Therapeutics Corporation
UTHR Healthcare Drug Manufacturers Specialty & Generic
United Therapeutics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 10.6% from fiscal 2024.
- Revenue
- +4.13%
- EPS
- −21.7%
- Free cash flow
- −63.7%
Quarter to September 2026, against a year earlier
Follow UTHR
Alert me
United Therapeutics Corporation (UTHR) Operating cash flow
United Therapeutics Corporation's operating cash flow for fiscal 2025 was $1.6B, up 17.6% from $1.3B in fiscal 2024. Over the twelve months to 30 September 2026 it was $1.4B. Over the past ten years it has ranged from −$206.6M (fiscal 2019) to $1.6B (fiscal 2025) — the current reading is the highest in ten years. Operating cash flow has risen for 4 consecutive fiscal years. United Therapeutics Corporation ranks 6th of 84 Drug Manufacturers Specialty & Generic companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $1.6B | 17.64% |
| FY2024 | $1.3B | 35.70% |
| FY2023 | $978.0M | 21.87% |
| FY2022 | $802.5M | 34.15% |
| FY2021 | $598.2M | (20.84%) |
| FY2020 | $755.7M | — |
| FY2019 | −$206.6M | — |
| FY2018 | $778.4M | 64.15% |
| FY2017 | $474.2M | (26.32%) |
| FY2016 | $643.6M | 68.13% |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | $313.6M | (32.31%) |
| Mar 2026 | $463.3M | 33.82% |
| Dec 2025 | $346.2M | (38.41%) |
| Sep 2025 | $562.1M | 193.22% |
| 42 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| TAK Takeda Pharmaceutical Co. compare | $11.6B |
| HLN Haleon PLC Sponsored ADR compare | $4.8B |
| ZTS Zoetis Inc. compare | $2.8B |
| VTRS Viatris Inc. compare | $2.5B |
| TEVA Teva Pharmaceutical Industries Ltd. compare | $1.8B |
| UTHR United Therapeutics Corporation | $1.4B |
| NBIX Neurocrine Biosciences, Inc. compare | $1.1B |
| ELAN Elanco Animal Health Incorporated compare | $617.0M |
| RDY Dr. Reddy's Laboratories Ltd compare | $313.0M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on UTHR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement